{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:26:56Z","timestamp":1791919616295,"version":"4.3.4"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cellsig.2023.110638","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T22:07:47Z","timestamp":1677017267000},"page":"110638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer"],"prefix":"10.1016","volume":"105","author":[{"given":"Anil Kumar","family":"Mavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Babita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2023.110638_bb0005","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2023.110638_bb0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2023.110638_bb0015","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1634\/theoncologist.2008-0166","article-title":"Cancer and immune response: old and new evidence for future challenges","volume":"13","author":"de la Cruz-Merino","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.cellsig.2023.110638_bb0020","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2023.110638_bb0025","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1002\/cam4.1700","article-title":"Interferon gamma in cancer immunotherapy","volume":"7","author":"Ni","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0030","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0035","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00262-012-1254-0","article-title":"Targeted immunotherapy of cancer with CAR T cells: achievements and challenges","volume":"61","author":"Lipowska-Bhalla","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cellsig.2023.110638_bb0040","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2023.110638_bb0045","first-page":"1","article-title":"Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2023.110638_bb0050","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1111\/j.1742-4658.2011.08207.x","article-title":"The association of heavy and light chain variable domains in antibodies: implications for antigen specificity","volume":"278","author":"Chailyan","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.cellsig.2023.110638_bb0055","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2023.110638_bb0060","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","article-title":"Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity","volume":"75","author":"Caruso","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2023.110638_bb0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellsig.2023.110638_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","article-title":"Designing chimeric antigen receptors to effectively and safely target tumors","volume":"33","author":"Jensen","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0075","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens","volume":"28","author":"Guest","year":"2005","journal-title":"J. Immunother."},{"key":"10.1016\/j.cellsig.2023.110638_bb0085","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane","volume":"180","author":"James","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0090","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0095","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/gt.2010.91","article-title":"Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc \u201cspacer\u201d domain in the extracellular moiety of chimeric antigen receptors avoids \u201coff-target\u201d activation and unintended initiation of an innate immune response","volume":"17","author":"Hombach","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.cellsig.2023.110638_bb0100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/gt.2015.4","article-title":"Inclusion of an IgG1-fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model","volume":"22","author":"Alm\u00e5sbak","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.cellsig.2023.110638_bb0105","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.cellsig.2023.110638_bb0115","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.4049\/jimmunol.1103495","article-title":"An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo","volume":"189","author":"Zhang","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellsig.2023.110638_bb0125","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellsig.2023.110638_bb0130","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellsig.2023.110638_bb0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0140","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0145","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.cellsig.2023.110638_bb0150","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.cellsig.2023.110638_bb0155","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6 \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0165","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia."},{"key":"10.1016\/j.cellsig.2023.110638_bb0170","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity."},{"key":"10.1016\/j.cellsig.2023.110638_bb0175","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cellsig.2023.110638_bb0180","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.cellsig.2023.110638_bb0185","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4161\/onci.19458","article-title":"Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy","volume":"1","author":"Song","year":"2012","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.cellsig.2023.110638_bb0190","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","article-title":"Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models","volume":"7","author":"Mata","year":"2017","journal-title":"Cancer Discov."},{"issue":"Jul","key":"10.1016\/j.cellsig.2023.110638_bb0195","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.cellsig.2023.110638_bb0200","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pul\u00e8","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellsig.2023.110638_bb0205","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol. Ther."},{"issue":"17","key":"10.1016\/j.cellsig.2023.110638_bb0210","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.cellsig.2023.110638_bb0215","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/cas.13239","article-title":"Clinical development of anti-CD 19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"108","author":"Makita","year":"2017","journal-title":"Cancer Sci."},{"issue":"18","key":"10.1016\/j.cellsig.2023.110638_bb0220","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood."},{"issue":"224","key":"10.1016\/j.cellsig.2023.110638_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"15","key":"10.1016\/j.cellsig.2023.110638_bb0230","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1200\/jco.2015.33.15_suppl.7010","article-title":"Efficacy and safety of CD19-targeted 19\u201328z CAR modified T cells in adult patients with relapsed or refractory B-ALL","volume":"33","author":"Park","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.cellsig.2023.110638_bb0235","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/jco.2015.33.15_suppl.3007","article-title":"Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer","volume":"33","author":"Beatty","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cellsig.2023.110638_bb0240","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood."},{"issue":"16","key":"10.1016\/j.cellsig.2023.110638_bb0245","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.cellsig.2023.110638_bb0250","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood."},{"issue":"9967","key":"10.1016\/j.cellsig.2023.110638_bb0255","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.cellsig.2023.110638_bb0260","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.yexcr.2011.08.015","article-title":"Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase","volume":"317","author":"Iri-Sofla","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.cellsig.2023.110638_bb0265","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bbagen.2013.09.029","article-title":"T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy","volume":"1840","author":"Jamnani","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"5\u20136","key":"10.1016\/j.cellsig.2023.110638_bb0270","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.cellsig.2023.110638_bb0275","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.cellsig.2023.110638_bb0280","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.4049\/jimmunol.1400864","article-title":"Thymic stromal lymphopoietin and cancer","volume":"193","author":"Kuan","year":"2014","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cellsig.2023.110638_bb0285","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL using chimeric antigen receptor\u2013expressing T cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin","year":"2015","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.cellsig.2023.110638_bb0290","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/blood.V126.23.1324.1324","article-title":"Clinical activity and persistence of anti-CD22 chimeric antigen receptor in children and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL)","volume":"126","author":"Fry","year":"2015","journal-title":"Blood."},{"issue":"15","key":"10.1016\/j.cellsig.2023.110638_bb0295","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1200\/jco.2015.33.15_suppl.3006","article-title":"Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition","volume":"33","author":"Turtle","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.cellsig.2023.110638_bb0305","first-page":"380","article-title":"T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have Long term persistence and induce durable remissions in children with relapsed","volume":"124","author":"Grupp","year":"2014","journal-title":"Refract. ALL. Blood."},{"issue":"2","key":"10.1016\/j.cellsig.2023.110638_bb0310","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.08.010","article-title":"Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents","volume":"334","author":"Sharifzadeh","year":"2013","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.cellsig.2023.110638_bb0315","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.cellsig.2023.110638_bb0320","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J. Clin. Investig."},{"issue":"7","key":"10.1016\/j.cellsig.2023.110638_bb0325","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"Van Der Stegen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"17","key":"10.1016\/j.cellsig.2023.110638_bb0330","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood."},{"issue":"16","key":"10.1016\/j.cellsig.2023.110638_bb0335","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.cellsig.2023.110638_bb0340","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nri1148","article-title":"Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?","volume":"3","author":"Croft","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.cellsig.2023.110638_bb0345","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications","volume":"27","author":"Riches","year":"2013","journal-title":"Hematol.\/Oncol. Clin."},{"issue":"12","key":"10.1016\/j.cellsig.2023.110638_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144787","article-title":"Evaluation of intracellular signaling downstream chimeric antigen receptors","volume":"10","author":"Karlsson","year":"2015","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.cellsig.2023.110638_bb0355","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4\u20131BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.cellsig.2023.110638_bb0360","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.cellsig.2023.110638_bb0365","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0370","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000437180","article-title":"T Cell Engineering","volume":"42","author":"Pircher","year":"2015","journal-title":"Prog. Tumor Res."},{"issue":"4","key":"10.1016\/j.cellsig.2023.110638_bb0375","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.cellsig.2023.110638_bb0380","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity."},{"issue":"95","key":"10.1016\/j.cellsig.2023.110638_bb0385","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.cellsig.2023.110638_bb0390","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology."},{"issue":"9","key":"10.1016\/j.cellsig.2023.110638_bb0395","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","article-title":"Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies","volume":"33","author":"Collinson-Pautz","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.cellsig.2023.110638_bb0400","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4\u20131BB costimulation","author":"Guedan","year":"2018","journal-title":"JCI Insight."},{"key":"10.1016\/j.cellsig.2023.110638_bb0405","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2023.110638_bb0410","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.cellsig.2023.110638_bb0415","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.cellsig.2023.110638_bb0420","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0425","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellsig.2023.110638_bb0430","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0435","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2019-131056","article-title":"A Bcma and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.cellsig.2023.110638_bb0440","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cellsig.2023.110638_bb0445","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0450","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2018-99-110142","article-title":"Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies","volume":"132","author":"Hossain","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.cellsig.2023.110638_bb0455","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0460","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellsig.2023.110638_bb0470","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2023.110638_bb0475","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2023.110638_bb0480","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0485","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1158\/1078-0432.CCR-10-0192","article-title":"Successful eradication of established peritoneal ovarian tumors in SCID-beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen","volume":"16","author":"Chekmasova","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2023.110638_bb0490","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","article-title":"Effective targeting of TAG72+ peritoneal ovarian tumors via regional delivery of CAR-engineered T cells","volume":"9","author":"Murad","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0495","unstructured":"Peter P.L (eds.) Tumor Microenvironment (Springer). https:\/\/www.springer.com\/gp\/book\/9783030388614."},{"key":"10.1016\/j.cellsig.2023.110638_bb0500","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2+ breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2023.110638_bb0505","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellsig.2023.110638_bb0510","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0515","series-title":"CAR T-cells Targeting the Integrin \u03b1v\u03b26 and Co-expressing the Chemokine Receptor cxcr2 Demonstrate Enhanced Homing and Efficacy Against Several Solid","author":"Whilding","year":"2023"},{"key":"10.1016\/j.cellsig.2023.110638_bb0520","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0525","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2023.110638_bb0530","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11427-016-5027-4","article-title":"Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.cellsig.2023.110638_bb0535","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0540","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor t cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellsig.2023.110638_bb0545","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0550","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","article-title":"Checkpoint blockade reverses anergy in IL-13R\u03b12 humanized scFv-based CAR T cells to treat murine and canine gliomas","volume":"11","author":"Yin","year":"2018","journal-title":"Mol. Ther. Oncolytics."},{"key":"10.1016\/j.cellsig.2023.110638_bb0555","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2023.110638_bb0565","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.cellsig.2023.110638_bb0570","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-CT036","article-title":"Abstract CT036: a phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: safety and efficacy","volume":"79","author":"Adusumilli","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2023.110638_bb0575","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellsig.2023.110638_bb0580","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellsig.2023.110638_bb0585","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.cellsig.2023.110638_bb0590","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellsig.2023.110638_bb0595","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","article-title":"Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer","volume":"25","author":"Mohammed","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellsig.2023.110638_bb0600","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0605","unstructured":"Research C for DE and. FDA Approves Tisagenlecleucel for B-cell ALL and Tocilizumab for Cytokine Release Syndrome. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome."},{"key":"10.1016\/j.cellsig.2023.110638_bb0610","unstructured":"Research C for DE. FDA Approves Axicabtagene Ciloleucel for Large B-cell Lymphoma. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma."},{"key":"10.1016\/j.cellsig.2023.110638_bb0615","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0620","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.cellsig.2023.110638_bb0625","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with b-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2023.110638_bb0630","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MOH.0000000000000559","article-title":"Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies","volume":"27","author":"Sterner","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0635","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0640","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.cellsig.2023.110638_bb0645","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0650","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.cellsig.2023.110638_bb0655","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","article-title":"The pharmacology of T cell therapies","volume":"8","author":"Milone","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.cellsig.2023.110638_bb0660","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0665","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cellsig.2023.110638_bb0670","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.canlet.2019.12.029","article-title":"Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches","volume":"473","author":"Tagliamonte","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cellsig.2023.110638_bb0675","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/1078-0432.CCR-19-1627","article-title":"Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy","volume":"26","author":"Hai","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2023.110638_bb0680","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Garcia-Carbonero","year":"2017","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.cellsig.2023.110638_bb0685","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","article-title":"Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells","volume":"106","author":"Heinzerling","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.cellsig.2023.110638_bb0690","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+: CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellsig.2023.110638_bb0700","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0705","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1080\/21691401.2019.1600529","article-title":"Using CuO nanoparticles and hyperthermia in radiotherapy of MCF-7 cell line: synergistic effect in cancer therapy","volume":"47","author":"Esmaeili Govarchin Ghaleh","year":"2019","journal-title":"Artif Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0710","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clim.2012.01.015","article-title":"Immunodominance: a pivotal principle in host response to viral infections","volume":"143","author":"Akram","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cellsig.2023.110638_bb0715","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"Frahm","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellsig.2023.110638_bb0725","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/gt.2015.41","article-title":"Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity","volume":"22","author":"Rodriguez-Garcia","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.cellsig.2023.110638_bb0730","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2023.110638_bb0735","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omto.2018.12.001","article-title":"Enhanced safety and efficacy of oncolytic VSV therapy by combination with T cell receptor transgenic T cells as carriers","volume":"12","author":"Melzer","year":"2019","journal-title":"Mol. Ther. Oncolytics."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656823000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656823000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:11:15Z","timestamp":1760267475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656823000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":142,"alternative-id":["S0898656823000529"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2023.110638","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2023.110638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110638"}}